SAN DIEGO, May 23, 2018 /PRNewswire/ -- NuVasive, Inc.
(NASDAQ: NUVA), the leader in spine technology innovation, focused
on transforming spine surgery with minimally disruptive,
procedurally-integrated solutions, today announced that the
Company's SpineTRACK Registry has reached a significant enrollment
milestone of 10,000 patients from more than 50 surgeons in
the United States since its
inception in 2011. This milestone illustrates not only the
continued utility of SpineTRACK to surgeon partners, but also
confirms the NuVasive commitment to research, data collection and
quality of care over the years.
The SpineTRACK Registry is a NuVasive-sponsored quality
improvement tool that tracks patient outcomes through their
treatment and recovery. As the longest-running registry currently
offered by any spine company, SpineTRACK serves as a comprehensive
and collaborative data collection solution for hospitals systems
and spine practices.
"We are proud to be a part of this important spine outcomes
registry," said Adam S. Kanter,
M.D., UPMC Chief of Spine. "SpineTRACK has become an integral part
of our practice here at UPMC and helps us better understand and
meet the needs of our patients. With the rapidly changing
healthcare landscape and growing importance of data collection,
SpineTRACK has enabled us to record and report our patients'
outcomes to provide the best care to our patients, accomplish our
academic and research goals, and promote cost-effective strategies
to our health system and administrators in support of value-based
policy conception and implementation. Incorporating SpineTRACK at
UPMC has proven to be a winning addition for all involved: the
patient, the surgeon, the hospital and the health plan."
The robust data collected in SpineTRACK enables surgeon and
hospital partners to use this valuable information when negotiating
with hospitals and payers, engaging with patients to track their
progress to better understand treatment benefits and evaluating
outcome variations to aid in providing the highest value of
care.
"Since announcing the Qualified Clinical Data Registry (QCDR)
designation earlier this year, we've seen a significant increase in
the adoption of SpineTRACK by both private practice physicians and
hospital systems," said Matt Link,
executive vice president, strategy, technology and corporate
development for NuVasive. "SpineTRACK is foundational in our
efforts to enhance the patient experience throughout the continuum
of care with advanced data analytics. These elements will help fuel
the future of Surgical Intelligence™ and continue to help
revolutionize spine care."
About NuVasive
NuVasive, Inc. (NASDAQ:
NUVA) is the leader in spine technology innovation, focused on
transforming spine surgery and beyond with minimally disruptive,
procedurally-integrated solutions designed to deliver reproducible
and clinically-proven surgical outcomes. The Company's portfolio
includes access instruments, implantable hardware, biologics,
software systems for surgical planning, navigation and imaging
solutions, magnetically adjustable implant systems for spine and
orthopedics, and intraoperative monitoring service offerings. With
$962 million in revenues (2016),
NuVasive has an approximate 2,300 person workforce in more than 40
countries serving surgeons, hospitals and patients. For more
information, please visit www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions
you that statements included in this news release that are not a
description of historical facts are forward-looking statements that
involve risks, uncertainties, assumptions and other factors which,
if they do not materialize or prove correct, could cause NuVasive's
results to differ materially from historical results or those
expressed or implied by such forward-looking statements. The
potential risks and uncertainties which contribute to the uncertain
nature of these statements include, among others, risks associated
with acceptance of the Company's surgical products and procedures
by spine surgeons, development and acceptance of new products or
product enhancements, clinical and statistical verification of the
benefits achieved via the use of NuVasive's products (including the
iGA® platform), the Company's ability to effectually manage
inventory as it continues to release new products, its ability to
recruit and retain management and key personnel, and the other
risks and uncertainties described in NuVasive's news releases and
periodic filings with the Securities and Exchange Commission.
NuVasive's public filings with the Securities and Exchange
Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect
events or circumstances arising after the date on which it was
made.
View original content with
multimedia:http://www.prnewswire.com/news-releases/nuvasive-spinetrack-registry-reaches-significant-enrollment-milestone-of-10-000-patients-300652287.html
SOURCE NuVasive, Inc.